CD4 and Huntington disease: In contrast, in treatment with omalizumab there were lower percentages of naïve cells and higher of central memory cells,when compared to NID, restoring values similar to those found in HD (naïve CD4: 43.40 [22.1–62] vs. 58.90 [23.6–71.9] %, p = 0.0025, and central memory CD4: 36.35 [19.5–62.9] vs. 29.10 [13.4–61.5] %, p = 0.0020; Figure 2).